Ignite Creation Date:
2025-12-24 @ 9:11 PM
Ignite Modification Date:
2025-12-28 @ 1:50 AM
Study NCT ID:
NCT04005404
Status:
COMPLETED
Last Update Posted:
2021-02-18
First Post:
2019-06-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Surgical Treatment of Hip Fractures Under Peripheral Regional Anesthesia
Sponsor:
Helios Research Center
Organization:
Study Overview
Official Title:
Surgical Treatment of Proximal Femoral Fractures Under Peripheral Regional Anesthesia. A Prospective Pilot Study
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique.
Detailed Description:
The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique.
After positioning on the non-fractured side, a double injection technique is used (dual guidance concept: nerve stimulation and sonography).
The injections are performed parasacrally (blockade of the sacral plexus under the piriformis muscle) and lumbar paravertebrally (psoas compartment block and transmuscular quadratus lumborum block). Per block 20 ml ropivacaine 0.375% is administered (total dose: 225mg ropivacaine).
The study examines the success rate (rate of successfully performed nerve blockade; need for supplemental medication: sufentanil and/or propofol; conversion rate to general anesthesia), circulatory stability (need for application of ephedrine or norepinephrine) and side effects.
After positioning on the non-fractured side, a double injection technique is used (dual guidance concept: nerve stimulation and sonography).
The injections are performed parasacrally (blockade of the sacral plexus under the piriformis muscle) and lumbar paravertebrally (psoas compartment block and transmuscular quadratus lumborum block). Per block 20 ml ropivacaine 0.375% is administered (total dose: 225mg ropivacaine).
The study examines the success rate (rate of successfully performed nerve blockade; need for supplemental medication: sufentanil and/or propofol; conversion rate to general anesthesia), circulatory stability (need for application of ephedrine or norepinephrine) and side effects.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: